Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery

This study is a prospective observational study. A total of 54 patients were included in this study. We observed the time from neostigmine administration to TOF ratio of 1.0.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recovery Time

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Bundang Hospital

Seongnam, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients undergoing elective thyroid surgery under general anesthesia
a body mass index of 18.5-25 kg/m2
Age ≥ 20

Exclusion criteria

Refused to participate
history of hypersensitivity to acetylcholinesterase inhibitor
neuromuscular disease
hepatic or renal dysfunction

Treatment and study plan

Neostigmine + Glycopyrrolate

Drug

a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.

Primary outcomes

Recovery time

Time frame: During surgery

Time from neostigmine administration to TOF ratio of 1.0

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Low-dose Neostigmine at TOF Ratio of 0.7 Accelerates Neuromuscular Recovery Without Adverse Effects: a Prospective Observational Study

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Dec 20, 2024
Registry last updated: Dec 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed